Splenic SUMO1 controls systemic inflammation in experimental sepsis

Splenic SUMO1 controls systemic inflammation in experimental sepsis

IntroductionThe recent discovery of TAK981(Subasumstat), the first-in-class selective inhibitor of SUMOylation, enables new immune treatments. TAK981 is already in clinical trials to potentiate immunotherapy in metastatic tumors and hematologic malignancies. Cancer patients have more than ten times...

Full description

Bibliographic Details
Main Authors: Ayman Youssef, Bilal Khan Mohammed, Abhishek Prasad, Angela del Aguila, Gabriel Bassi, Wei Yang, Luis Ulloa
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Subjects:
sepsis
SUMO
TAK981
spleen
infection
organ function
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1200939/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1200939/full

Similar Items